A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200 mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.
Blanke
Charles D
CD
Oregon Health and Science University Cancer Institute, Portland, OR, USA. blankec@ohsu.edu
Mattek
Nora C
NC
Deloughery
Thomas G
TG
Koop
Dennis R
DR
D015746:Abdominal Pain; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000633:toxicity*; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage; D003967:Diarrhea; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage
D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; D002955:Leucovorin; D005472:Fluorouracil